PL378432A1 - Inhibitory p38 i sposoby ich zastosowania - Google Patents

Inhibitory p38 i sposoby ich zastosowania

Info

Publication number
PL378432A1
PL378432A1 PL378432A PL37843204A PL378432A1 PL 378432 A1 PL378432 A1 PL 378432A1 PL 378432 A PL378432 A PL 378432A PL 37843204 A PL37843204 A PL 37843204A PL 378432 A1 PL378432 A1 PL 378432A1
Authority
PL
Poland
Prior art keywords
inhibitors
methods
Prior art date
Application number
PL378432A
Other languages
English (en)
Other versions
PL214032B1 (pl
Inventor
Mark Munson
David A. Mareska
Youngboo Kim
Robert Groneberg
James Rizzi
Martha Rodriguez
Ganghyeok Kim
Guy Vigers
Chang Rao
Devan Balachari
Darren Harvey
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,164 external-priority patent/US7135575B2/en
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of PL378432A1 publication Critical patent/PL378432A1/pl
Publication of PL214032B1 publication Critical patent/PL214032B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
PL378432A 2003-03-03 2004-02-25 Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38 PL214032B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/378,164 US7135575B2 (en) 2003-03-03 2003-03-03 P38 inhibitors and methods of use thereof
US10/688,849 US20040180896A1 (en) 2003-03-03 2003-10-15 P38 inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
PL378432A1 true PL378432A1 (pl) 2006-04-03
PL214032B1 PL214032B1 (pl) 2013-06-28

Family

ID=32965317

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378432A PL214032B1 (pl) 2003-03-03 2004-02-25 Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38

Country Status (12)

Country Link
US (1) US7521447B2 (pl)
EP (1) EP1606283B1 (pl)
JP (1) JP4617299B2 (pl)
KR (1) KR101099281B1 (pl)
AU (1) AU2004218463B2 (pl)
CA (1) CA2517517C (pl)
IS (1) IS2675B (pl)
MX (1) MXPA05009459A (pl)
NO (1) NO328913B1 (pl)
PL (1) PL214032B1 (pl)
RU (1) RU2357957C2 (pl)
WO (1) WO2004078116A2 (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050071598A (ko) * 2002-10-24 2005-07-07 메르크 파텐트 게엠베하 라프-키나아제 억제제로서의 메틸렌 우레아 유도체
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
CN1934111A (zh) 2004-02-27 2007-03-21 霍夫曼-拉罗奇有限公司 杂芳基稠合的吡唑并衍生物
EA012119B1 (ru) 2004-08-12 2009-08-28 Пфайзер Инк. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
KR20070058689A (ko) * 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조 방법
MX2007005291A (es) * 2004-11-02 2007-07-19 Pfizer Metodos para preparar compuestos de indazol.
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
WO2006122230A1 (en) * 2005-05-11 2006-11-16 Array Biopharma Inc. P38 inhibitors and methods of use thereof
KR101011958B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸
BRPI0614884A2 (pt) * 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
EP1931668A2 (en) * 2005-09-16 2008-06-18 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
WO2007047397A2 (en) * 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
WO2007059219A1 (en) * 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
WO2007063868A1 (ja) * 2005-11-29 2007-06-07 Toray Industries, Inc. アリールメチレンウレア誘導体及びその用途
RS52298B (sr) * 2006-01-31 2012-12-31 Array Biopharma Inc. Inhibitori kinaze i postupak njihove upotrebe
CA2647949A1 (en) * 2006-03-29 2007-11-08 Array Biopharma Inc. P38 inhibitors and methods of use thereof
CA2927045A1 (en) * 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
PL2101759T3 (pl) * 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
EP2091952A1 (en) * 2006-12-19 2009-08-26 F. Hoffmann-Roche AG Pyrazolo ý3, 4 -d¨pyrimidine p38 map kinase inhibitors
MX2009006401A (es) * 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2009015000A1 (en) * 2007-07-25 2009-01-29 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
KR20110017007A (ko) * 2008-07-15 2011-02-18 에프. 호프만-라 로슈 아게 치환된 인돌릴 및 인다졸릴 유도체 및 이들의 용도
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP2012504591A (ja) 2008-10-02 2012-02-23 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
MX2011006219A (es) * 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CA2776944A1 (en) * 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
MX2013010513A (es) 2011-03-16 2013-10-07 Hoffmann La Roche Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
MY167216A (en) * 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
SI2819998T1 (sl) * 2012-03-01 2022-07-29 Array Biopharma Inc. Kristalinske oblike 1-(3-tert-butil-1-P-tolil-1H-pirazol-5-il)-3- (5-fluoro-2-(1-(2-hidroksietil)-1H-indazol-5-iloksi)benzil)urea hidroklorida
US20150225369A1 (en) * 2012-08-29 2015-08-13 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
WO2014134313A1 (en) 2013-02-27 2014-09-04 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
WO2014145485A2 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof
US9962357B2 (en) * 2013-10-18 2018-05-08 West Virginia University Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
CN104974160B (zh) * 2014-04-08 2017-12-05 辰欣药业股份有限公司 2‑甲基吡唑并[1,5‑a]嘧啶‑6‑羧酸衍生物及其应用
EP3233797B1 (en) * 2015-01-18 2019-05-08 SRI International Inc. Map4k4 (hgk) inhibitors
RU2675496C1 (ru) * 2017-03-31 2018-12-20 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения алкиловых эфиров гидроксибензойных кислот
CN108947879B (zh) * 2017-05-17 2022-06-28 中国科学院上海药物研究所 Prmt i型抑制剂及其制备方法和用途
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4051665A1 (en) 2019-10-28 2022-09-07 Teva Pharmaceuticals International GmbH Solid state forms of arry-797 and process for preparation thereof
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN113354558B (zh) * 2021-07-12 2022-03-11 无锡双启科技有限公司 一种2-氨基-5-氟苯腈的制备方法
CN115850179B (zh) * 2022-12-13 2025-03-25 北京科翔中升医药科技有限公司 一种氘代吲唑类mapk抑制剂药物及用途
WO2025056518A1 (en) * 2023-09-11 2025-03-20 Univerza V Ljubljani 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998060A (ja) * 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
JPS6368568A (ja) * 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IE910278A1 (en) * 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
BR9305569A (pt) * 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
AU682947B2 (en) * 1994-05-27 1997-10-23 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
KR19990064117A (ko) 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5965583A (en) * 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1019394A1 (en) * 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9812944A (pt) * 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
EP1028953A1 (en) * 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
CA2360934A1 (en) * 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
JP2002539206A (ja) * 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
ATE278674T1 (de) * 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
AU4063600A (en) * 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
JP2003500403A (ja) 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU1899501A (en) 1999-11-27 2001-06-04 Dong Wha Pharmaceutical Industrial Co., Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives
AU4890301A (en) * 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
EP1341782A2 (en) 2000-11-20 2003-09-10 Scios Inc. Inhibitors of p38 kinase
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
HUP0303415A2 (hu) 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
WO2003087072A1 (en) * 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
ES2273047T3 (es) * 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
WO2006122230A1 (en) * 2005-05-11 2006-11-16 Array Biopharma Inc. P38 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
WO2004078116A3 (en) 2004-10-14
EP1606283A4 (en) 2007-05-23
RU2005131197A (ru) 2006-05-10
WO2004078116A9 (en) 2008-09-12
EP1606283B1 (en) 2008-10-08
MXPA05009459A (es) 2006-05-17
KR101099281B1 (ko) 2011-12-26
CA2517517A1 (en) 2004-09-16
RU2357957C2 (ru) 2009-06-10
EP1606283A2 (en) 2005-12-21
JP2006519259A (ja) 2006-08-24
AU2004218463A1 (en) 2004-09-16
AU2004218463B2 (en) 2009-07-16
NO20054453D0 (no) 2005-09-26
NO20054453L (no) 2005-11-29
WO2004078116A2 (en) 2004-09-16
NO328913B1 (no) 2010-06-14
JP4617299B2 (ja) 2011-01-19
US7521447B2 (en) 2009-04-21
CA2517517C (en) 2012-12-18
KR20050106484A (ko) 2005-11-09
IS8037A (is) 2005-09-21
US20040192653A1 (en) 2004-09-30
PL214032B1 (pl) 2013-06-28
IS2675B (is) 2010-09-15

Similar Documents

Publication Publication Date Title
EG27049A (en) P38 inhibitors and methods of use thereof
EP1606283A4 (en) P38 INHIBITOR AND METHOD OF USE THEREOF
AU2003303128A8 (en) Inhibitors and methods of use thereof
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
PH12012501372A1 (en) Proteasome inhibitors and methods of using the same
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
EP1507756A4 (en) CCR9 INHIBITORS AND USE THEREOF
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
AU2003259735A8 (en) Small-mer compositions and methods of use
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
IL172986A0 (en) Hairpin -labeled probes and methods of use
PT1592686E (pt) Inibidores de girase e suas utilizações
PL378331A1 (pl) Tetracykliczne pochodne benzamidowe i sposoby ich stosowania
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
AU2003299441A8 (en) Nf-hev compositions and methods of use
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
ZA200601293B (en) Proteasome inhibitors and methods of using the same
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1789437A4 (en) INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
EP1883404A4 (en) P38 INHIBITORS AND METHODS OF USE
EP1605812A4 (en) INSUFFLATOR AND METHOD OF USE
AU2003238948A8 (en) Caspase-1 inhibitors and methods for their use